Crohn's disease (CD), ulcerative colitis (UC), and colitis unclassified, collectively defined as inflammatory bowel disease (IBD), are the consequence of chronic inflammatory reactions in the gastrointestinal tissue. Endoscopy with biopsies is the mainstay in the diagnosis of this inflammation and is also important in the assessment of disease activity and monitoring of treatment. Furthermore, mucosal healing is increasingly becoming a therapeutic target for treatment of IBD and the golden standard of assessing it is endoscopy. However, due to the costs, invasiveness, and to limited endoscopic capacity, the need is strong for reliable surrogate markers of intestinal inflammation. Bowel contents, being in close contact with intestinal mucosa, can take up molecules that are measurable from stool samples and thus can serve as markers of inflammation. The fecal neutrophil-derived biomarkers, especially calprotectin and lactoferrin, have several features of an ideal test for detecting intestinal inflammation: they are noninvasive, simple, and low in cost. The utility of these biomarkers in distinguishing IBD from noninflammatory conditions such as irritable bowel syndrome is well documented. They correlate closely with endoscopic activity both in CD and UC. They allow serial monitoring of disease activity and of treatment success, and can even serve in predicting clinical relapse in unsymptomatic patients or sustained remission after induction with TNF-α-blocking agents. In this review an overview will be given to the role of fecal neutrophil-derived biomarkers calprotectin and lactoferrin in diagnostics and prognostics of IBD.

Keywords:
Calprotectin, Lactoferrin, Disease activity, Ulcerative colitis, Crohn’s disease
1.
Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkuhn T, Orchard TR, Rogler G, Louis E, Kupcinkas L, Mantzaris G, Travis S, Stange E-F: The second European evidence-based consensus on the diagnosis and management of Crohn's disease. Definitions and diagnosis. J Crohns Colitis 2010;4:7-27.
2.
Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G: Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. 1. Definitions and diagnosis. J Crohns Colitis 2012;6:965-990.
3.
Rutgeerts P, Vermeire S, Van Assche G: Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007;56:453-455.
4.
Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fagerhol M, Bjarnason I: A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-513.
5.
Fagerhol MK, Dale I, Andersson T: Release and quantitation of a leucocyte-derived protein (L1). Scand J Haematol 1980;24:393-398.
6.
Dale I, Fagerhol MK, Naesgaard I: Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen. Eur J Biochem 1983;134:1-6.
7.
Foell D, Wittkowski H, Ren Z, Turton J, Pang G, Daebritz J, Ehrchen J, Heidemann J, Borody T, Roth J, Clancy R: Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol 2008;216:183-192.
8.
Dale I, Brandtzaeg P, Fagerhol MK, Scott H: Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin. Am J Clin Pathol 1985;84:24-34.
9.
Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, Dale I: Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997;50:113-123.
10.
Berntzen HB, Olmez U, Fagerhol MK, Munthe E: The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 1991;20:74-82.
11.
Cuida M, Halse AK, Johannessen AC, Tynning T, Jonsson R: Indicators of salivary gland inflammation in primary Sjögren's syndrome. Eur J Oral Sci 1997;105:228-233.
12.
Holt J, Fagerhol MK, Dale I: Quantitation of a leukocyte protein (L1) in urine. Acta Paediatr Scand 1983;72:615-616.
13.
Laforgia N, Baldassarre ME, Pontrelli G, Indrio F, Altomare MA, Di Bitonto G, Mautone A: Calprotectin levels in meconium. Acta Paediatr 2003;92:463-466.
14.
Olafsdottir E, Aksnes L, Fluge G, Berstad A: Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr 2002;91:45-50.
15.
Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F, Scalici C, Montalto G, Di Fede G, Rini G, Notarbartolo A, Averna MR: Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003;49:861-867.
16.
Fagerberg UL, Loof L, Merzoug RD, Hansson LO, Finkel Y: Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr 2003;37:468-472.
17.
Roseth AG, Schmidt PN, Fagerhol MK: Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50-54.
18.
Husebye E, Ton H, Johne B: Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol 2001;96:2683-2687.
19.
Naismith GD, Smith LA, Barry SJE, et al: A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment Pharmacol Ther 2013;37:613-621.
20.
Roseth AG, Fagerhol MK, Aadland E, Schjonsby H: Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793-798.
21.
Ton H, Brandsnes, Dale S, Holtlund J, Skuibina E, Schjonsby H, Johne B: Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41-54.
22.
Von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, Paraskeva P, Tekkis PP: Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803-813.
23.
Damms A, Bischoff SC: Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int J Colorectal Dis 2008;23:985-992.
24.
Otten CMT, Kok L, Witteman BJM, Baumgarten R, Kampman E, Moons KGM, de Wit NJ: Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med 2008;46:1275-1280.
25.
Kolho K-L, Turner D, Veereman-Wauters G, Sladek M, de Ridder L, Shaoul R, Paerregaard A, Amil Dias J, Koletzko S, Nuti F, Bujanover Y, Staiano A, Bochenek K, Finnby L, Levine A, Veres G: Rapid test for fecal calprotectin levels in children with Crohn disease. J Pediatr Gastroenterol Nutr 2012;55:436-439.
26.
Hessels J, Douw G, Yildirim DD, Meerman G, van Herwaarden MA, van den Bergh FA: Evaluation of Prevent ID and Quantum Blue rapid tests for fecal calprotectin. Clin Chem Lab Med 2012;50:1079-1082.
27.
Montalto M, Santoro L, Curigliano V, D'Onofrio F, Cammarota G, Panunzi S, Ricci R, Gallo A, Grieco A, Gasbarrini A, Gasbarrinin G: Faecal calprotectin concentrations in untreated coeliac patients. Scand J Gastroenterol 2007;42:957-961.
28.
Wildt S, Nordgaard-Lassen I, Bendtsen F, Rumessen JJ: Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol 2007;19:567-574.
29.
Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I: Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-460.
30.
Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, Sterpi C, Marchi S, Maltinti G: Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003;35:642-647.
31.
Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB: Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004;20:615-621.
32.
Konikoff MR, Denson LA: Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:524-534.
33.
D'Inca R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG, Martines D, Sturniolo GC: Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007;22:429-437.
34.
Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F: Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008;14:32-39.
35.
Schroder O, Naumann M, Shastri Y, Povse N, Stein J: Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther 2007;26:1035-1042.
36.
Fagerberg UL, Loof L, Myrdal U, Hansson LO, Finkel Y: Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005;40:450-455.
37.
Kostakis ID, Cholidou KG, Vaiopoulos AG, Vlachos IS, Perrea D, Vaos G: Fecal calprotectin in pediatric inflammatory bowel disease: a systematic review. Dig Dis Sci 2013;58:309-319.
38.
Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE: Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;33:14-22.
39.
Summerton CB, Longlands MG, Wiener K, Shreeve DR: Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002;14:841-845.
40.
Bremner A, Roked S, Robinson R, Phillips I, Beattie M: Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr 2005;94:1855-1858.
41.
Thjodleifsson B, Sigthorsson G, Cariglia N, Reynisdottir I, Gudbjartsson DF, Kristjansson K, Meddings JB, Gudnason V, Wandall JH, Andersen LP, Sherwood R, Kjeld M, Oddsson E, Gudjonsson H, Bjarnason I: Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology 2003;124:1728-1737.
42.
Van Rheenen PF, Van de Vijver E, Fidler V: Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:3369.
43.
Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ, Zinsmeister AR: Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 2000;95:2831-2837.
44.
Licata A, Randazzo C, Cappello M, Calvaruso V, Butera G, Florena AM, Peralta S, Camma C, Craxi A: Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea. J Clin Gastroenterol 2012;46:504-508.
45.
Silberer H, Kuppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, Kempf A, Schmidt-Gayk H: Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab 2005;51:117-126.
46.
Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, Dobos GJ, Roth J, Foell D: Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706-1713.
47.
Canani RB, de Horatio LT, Terrin G, Romano MT, Miele E, Staiano A, Rapacciuolo L, Polito G, Bisesti V, Manguso F, Vallone G, Sodano A, Troncone R: Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2006;42:9-15.
48.
Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F: Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum 2007;50:1697-1706.
49.
Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ: Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-E, CRP, and clinical indices. Am J Gastroenterol 2008;103:162-169.
50.
Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S: Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008;14:669-673.
51.
D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, Van Olmen G, Rutgeerts P: Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218-2224.
52.
Roseth AG, Aadland E, Jahnsen J, Raknerud N: Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176-180.
53.
Bunn SK, Bisset WM, Main MJ, Golden BE: Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;32:171-177.
54.
Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F: Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis 2013;19:332-341.
55.
Roseth AG, Aadland E, Grzyb K: Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1017-1020.
56.
Sipponen T, Savilahti E, Kolho K-L, Nuutinen H, Turunen U, Farkkila M: Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40-46.
57.
Sipponen T, Karkkainen P, Savilahti E, Kolho K-L, Nuutinen H, Turunen U, Farkkila M: Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008;28:1221-1229.
58.
Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F: Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162-169.
59.
Sipponen T, Savilahti E, Karkkainen P, Kolho K-L, Nuutinen H, Turunen U, Farkkila M: Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-α therapy for Crohn's disease. Inflamm Bowel Dis 2008;14:1392-1398.
60.
De Vos M, Dewit O, D'Haens G, Baert F, Fontaine F, Vermeire S, Franchimont D, Moreels T, Staessen D, Terriere L, Vander Cruyssen B, Louis E: Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF-naive patients with ulcerative colitis. J Crohns Colitis 2012;6:557-562.
61.
Molander P, af Bjorkesten C-G, Mustonen H, Haapamaki J, Vauhkonen M, Kolho K-L, Farkkila M, Sipponen T: Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis 2012;18:2011-2017.
62.
Laharie D, Mesli S, El Hajbi F, Chabrun E, Chanteloup E, Capdepont M, Razaire S, de Ledinghen V, Zerbib F: Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther 2011;34:462-469.
63.
Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, Shand AG, Bartolo DC, Wilson RG, Dunlop MG, Arnott ID, Satsangi J: Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009;104:673-678.
64.
Turner D, Leach ST, Mack D, Uusoue K, McLernon R, Hyams J, Leleiko N, Walters TD, Crandall W, Markowitz J, Otley AR, Griffiths AM, Day AS: Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010;59:1207-1212.
65.
Turner D, Mack D, Leleiko N, Walters TD, Uusoue K, Leach ST, Day AS, Crandall W, Silverberg MS, Markowitz J, Otley AR, Keljo D, Mamula P, Kugathasan S, Hyams J, Griffiths AM: Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010;138:2282-2291.
66.
Mao R, Xiao Y-I, Gao X, Chen B-I, He Y, Yang L, Hu P-J, Chen M-H: Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012;18:1894-1899.
67.
Louis E, Mary J, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, De Vos M, Porcher R, Paintaud G, Piver E, Colombel J-F, Lemann M: Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63-70.
68.
Kayazawa M, Saitoh O, Kojima K, Nakagawa K, Tanaka S, Tabata K, et al: Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 2002;97:360-369.
69.
Dai J, Liu W-Z, Zhao Y, Hu Y, Ge Z: Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol 2007;42:1440-1444.
70.
Uchida K, Matsuse R, Tomita S, Sugi K, Saitoh O, Ohshiba S: Immunochemical detection of human lactoferrin in feces as a new marker for inflammatory gastrointestinal disorders and colon cancer. Clin Biochem 1994;27:259-264.
71.
Hille A, Schmidt-Giese E, Hermann RM, Hermann MKA, Rave-Frank M, Schirmer M, Christansen H, Hess CF, Ramadori G: A prospective study of faecal calprotectin and lactoferrin in the monitoring of acute radiation proctitis in prostate cancer treatment. Scand J Gastroenterol 2008;43:52-58.
72.
Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB: Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003;98:1309-1314.
73.
Sidhu R, Sanders D, Wilson P, Foye L, Morley S, McAlindon ME: Faecal lactoferrin, capsule endoscopy and Crohn's disease. Is there a three-way relationship? A pilot study. J Gastrointest Liver Dis 2010;19:257-260.
74.
Gisbert JP, McNicholl AG: Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009;41:56-66.
75.
Walker TR, Land ML, Kartashov A, Saslowsky TM, Lyerly DM, Boone JH, Rufo PA: Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:414-422.
76.
Parsi MA, Shen B, Achkar JP, Remzi FF, Goldblum JR, Boone J, Lin D, Connor JT, Fazio VW, Lashner BA: Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 2004;126:1280-1286.
77.
Langhorst J, Elsenbruch S, Mueller T, Rueffer A, Spahn G, Michalsen A, Dobos GJ: Comparison of four neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 2005;11:1085-1091.
78.
Jones J, Loftus EV Jr, Panaccione R, Chen Li-Sheng, Peterson S, McConnell J, Baudhuin L, Hanson K, Feagan BG, Harmsen SW, Zinsmeister AR, Helou E, Sandborn WJ: Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6:1218-1224.
79.
Scarpa M, D'Inca R, Basso D, Ruffolo C, Polese L, Bertin E, Luise A, Frego M, Plebani M, Sturniolo GC, D'Amico DF, Angriman I: Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease. Dis Colon Rectum 2007;50:861-869.
80.
Buderus S, Boone J, Lyerly D, Lentze MJ: Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig Dis Sci 2004;49:1036-1039.
81.
Sipponen T, Bjorkesten C-G, Farkkila M, Nuutinen H, Savilahti E, Kolho K-L: Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 2010;45:325-331.
82.
Gisbert JP, Bermejo F, Perez-Calle JL, Taxonera C, Vera I, McNicholl, AG, Algaba A, Lopez P, Lopez-Palacios N, Calvo M, Gonzalez-Lama Y, Carneros JA, Velasco M, Mate J: Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190-1198.
83.
Thomas P, Rihani H, Roseth A, Sigthorsson G, Price A, Nicholls RJ, Bjarnason I: Assessment of ileal pouch inflammation by single-stool calprotectin assay. Dis Colon Rectum 2000;43:214 -220.
84.
Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Aiello F: Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis 2009;24:49-55.
85.
Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, Bjarnason I: High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999;45:362-366.
86.
Carroll D, Corfield A, Spicer R, Cairns P: Faecal calprotectin concentrations and diagnosis of necrotising enterocolitis. Lancet 2003;361:310-311.
87.
Sudan D, Vargas L, Sun Y, Bok L, Dijkstra G, Langnas A: Calprotectin: a novel noninvasive marker for intestinal allograft monitoring. Ann Surg 2007;246:311-315.
88.
Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M: Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008;14:5584-5589.
89.
Tomomasa T, Tajiri H, Kagimoto S, Shimizu T, Yoden A, Ushijima K, Uchida K, Kaneko H, Abukawa D, Konno M, Maisawa S, Kohsaka T, Kobayashi A; Japanese Study Group for Pediatric Ulcerative Colitis: Leukocytapheresis in pediatric patients with ulcerative colitis. J Pediatr Gastroenterol Nutr 2011;53:34-39.
90.
Hämäläinen A, Sipponen T, Kolho K-L: Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol 2011;17:5166-5171.
91.
Gerasimidis K, Nikolaou CK, Edwards CA, McGrogan P: Serial fecal calprotectin changes in children with Crohn's disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J Clin Gastroenterol 2011:45:234-239.
92.
Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, Ponich T, Fox I, Feagan BG: Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study 2012;18:1470-1479.
93.
Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I: Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.
94.
Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, Ricchiuti A, Marchi S, Bottai M: Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005;54:364-368.
95.
D'Inca R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, Oliva L, Sturniolo GC: Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008;103:2007-2014.
96.
García-Sánchez V, Iglesias Flores E, Gonzalez R, Gisbert JP, Gallardo-Valverde JM, Gonzalez-Galilea A, Naranjo-Rodriguez A, de Dios Vega JF, Muntante J, Gomez Camacho F: Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis. J Crohns Colitis 2010;4:144-152.
97.
Kallel L, Imen Ayadi I, Matri S, Fekih M, Ben Mahmoud N, Feki M, Karoui S, Zouari B, Boubaker J, Naziha Kaabachi N, Filali A: Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol 2010, 22:340-345.
98.
Sipponen T, Kolho K-L: Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol 2010;45:872-877.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.